CBP/β-catenin inhibitor · small molecule
E7386
1 active trials, targeting CBP/β-catenin. Not approved for any biomarker on marked.bio yet.
Counts only trials that select patients by one of the biomarkers on marked.bio, not every trial of this drug.
Biomarkers
| Biomarker | Active trials | All trials | Furthest active phase |
|---|---|---|---|
| MSI-H / dMMR | 1 | 1 | Phase 1/2 |
Sponsors
Industry sponsors leading active biomarker-selected trials of E7386.
- Eisai 1
Trials
1 of 1 trials shown
-
A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor
E7386lenvatinibdoxorubicinpaclitaxel
Immune checkpoint inhibitor for participants with microsatellite instability-high (MSI-H) CRC
MSI-H / dMMREndometrial Neoplasms, Neoplasms, Carcinoma, Hepatocellular, Liver Neoplasms
No trials match these filters.